For the full information on the PhD projects available, please see below.
Thrombosis, encompassing arterial and venous thrombosis, and thromboinflammation, impacts the pathophysiology of major health issues such as heart attack, stroke, cancer and infection. Thrombosis contributes to an estimated 40% of cardiovascular deaths in the EU, and over €200 billion a year to the EU economy.
Current therapy in the prevention of arterial thrombotic events includes drugs that suppress platelet function. While effective in a large proportion of patients, a significant number of patients have further thrombotic episodes that result in death, while approximately 5% of treated patients develop clinically relevant bleeding which may require blood transfusion and can be fatal. With an ageing population, who are at a greater risk of thrombosis, the shortfall in available therapy regimes is a growing unmet clinical need in the EU. This presents a major societal problem and a need to develop new and improved anti-platelet agents that effectively target thrombosis whilst preserving haemostasis. This is the major goal of TAPAS.
Early Stage Researchers (ESRs) Projects
ESR 1: Regulation of GPVI clustering: role of the cytoskeleton
ESR 2: The role of membrane microdomains in GPVI signalling
ESR 3: Innovative methods to study proteomic signatures of glycoprotein receptor signalling
ESR 4: Role of (patho)physiological flow on receptor clustering and signalling
ESR 5: Artificial lipid membranes to study GPVI receptor clustering and signalling
ESR 7: The role of platelet receptors in inflammatory bleeding
ESR 8: Vessel-on-a-chip as novel model to assess receptor function in thrombosis and haemostasis
ESR 9: Modelling of CLEC-2 clustering and signalling
ESR 10: Modelling of collagen receptor clustering and signalling
ESR 11: Integrating omics, functional datasets and microscopy to predict thrombosis and haemostasis
ESR 12: High throughput screening of small molecule inhibitors of receptor signalling
ESR 13: Generation and functional testing of novel biologics targeting glycoprotein receptors
ESR 14: CRISPR/Cas9 based generation of genetic mouse models to assess platelet receptor targeting
ESR 15: High throughput screening of small molecule inhibitors of CLEC-2